04.01.2014 Views

Broker-Dealer Litigation - Greenberg Traurig LLP

Broker-Dealer Litigation - Greenberg Traurig LLP

Broker-Dealer Litigation - Greenberg Traurig LLP

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

were disclosed by the timely filing of Form 4s with the SEC. With respect to grants for which<br />

Form 4s were not necessarily timely filed, the court credited the defendants’ arguments that the<br />

plaintiffs used inconsistent standards to measure the gains that accrued after options were<br />

granted, thus undercutting the force of their backdating allegations. The defendants also<br />

convinced the court that the plaintiffs had improperly cherry-picked a small subset of option<br />

grants to allege circumstantial backdating, ignoring the larger number of grants that bore no<br />

indicia that they were backdated. With respect to the plaintiffs’ claims that Apollo overstated its<br />

net income and understated its compensation expenses as a result of granting stock options below<br />

their fair market value, the court similarly held that these allegations failed to meet the applicable<br />

pleading standards.<br />

Nguyen v. Radient Pharms. Corp., 2011 U.S. Dist. LEXIS 124631 (C.D. Cal. Oct. 26, 2011).<br />

O.1<br />

Plaintiffs filed a complaint alleging federal securities law violations against a small<br />

pharmaceutical company and related individuals. The defendants moved to dismiss, arguing that<br />

the complaint failed to comply with the applicable pleading requirements and, in particular,<br />

failed to identify the allegedly material misrepresentations with the particularity required by Rule<br />

9(b) and the Private Securities <strong>Litigation</strong> Reform Act of 1995. The court disagreed and denied<br />

the motion, holding that the plaintiffs adequately specified which statements were misleading<br />

and stated the reasons why those statements were misleading. Specifically, the plaintiffs<br />

properly accused the defendants of misstating that that the company was conducting a drug study<br />

with the Mayo Clinic and referring to that study as the “Mayo study” when, in fact, the company<br />

had only entered into a collaboration agreement with a separate laboratory division of the Mayo<br />

Clinic known as Mayo Validation Support Services.<br />

O.1.<br />

Anschutz Corp. v. Merrill Lynch & Co., Inc., 785 F. Supp. 2d 799 (N.D. Cal. 2011)<br />

The plaintiff, an investor in auction rate securities (“ARS”) brought suit against sellers of<br />

ARS and securities ratings agencies, accusing the sellers of market manipulation in violation of<br />

the Securities Exchange Act of 1934 and California state securities laws, and accusing the ratings<br />

agencies of negligent misrepresentation. The defendants moved to dismiss, and with one limited<br />

exception, the court denied the motion. With respect to the market manipulation claims against<br />

the sellers, the court found that the allegations were pleaded with sufficient particularity to<br />

satisfy Rule 9(b), rejecting the defendants’ argument that their disclosure of the fact that they<br />

“may” place support bids in auctions precluded claims of manipulation. The defendants’<br />

disclosure was not sufficient to cover the allegation made by plaintiffs that in the auctions at<br />

issue, the defendants had participated in every auction and bid for 100% of the issue at every<br />

auction. With respect to the negligent misrepresentation claims against the ratings agencies, the<br />

court noted that district courts within the Ninth Circuit held Rule 9(b) applicable to such claims<br />

and therefore, although the Ninth Circuit had not decided the question, the court assumed that the<br />

heightened pleading standard applied. The court found the plaintiff’s allegations against the<br />

rating agencies sufficient to meet the heightened standard, particularly in light of the rating<br />

agencies’ involvement in structuring the securities at issue, their knowledge that the securities<br />

359

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!